Ticagrelor yields consistent dose-dependent inhibition of ADP-induced platelet aggregation in patients with atherosclerotic disease regardless of genotypic variations inP2RY12, P2RY1,andITGB3-Reference-Cited by-同舟云学术

Ticagrelor yields consistent dose-dependent inhibition of ADP-induced platelet aggregation in patients with atherosclerotic disease regardless of genotypic variations inP2RY12, P2RY1,andITGB3

Published:2009-01 Issue:5 Volume:20 Page:341-348
ISSN:0953-7104
Container-title:Platelets
language:en
Short-container-title:Platelets

Author:

Storey Robert F.,Melissa Thornton S.,Lawrance Rachael,Husted Steen,Wickens Mark,Emanuelsson Håkan,Cannon Christopher P.,Heptinstall Stan,Armstrong Martin

Publisher

Informa UK Limited

Subject

Hematology,General Medicine

Link

http://www.tandfonline.com/doi/pdf/10.1080/09537100903075324

Reference29 articles.

1. Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation

2. Biology and Pharmacology of the Platelet P2Y12 Receptor

3. Clopidogrel: a review of its mechanism of action

4. Clopidogrel for Coronary Stenting

5. Clopidogrel Resistance Is Associated With Increased Risk of Recurrent Atherothrombotic Events in Patients With Acute Myocardial Infarction

Cited by 63 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Identification of Key Genes and Biological Pathways in Cardiac Arrest by Integrated Bioinformatics and Next Generation Sequencing Data Analysis;2024-08-19

2. CYP2C19 Genetic Testing for Oral P2Y12 Inhibitor Therapy: A Scientific Statement From the American Heart Association;Circulation;2024-08-06

3. Advances and Perspectives in methods for identifying high platelet reactivity;Heliyon;2023-12

4. Ticagrelor inhibits platelet aggregation and reduces inflammatory burden more than clopidogrel in patients with stages 4 or 5 chronic kidney disease;Vascular Pharmacology;2023-02

5. Pharmacogenetics of Antiplatelet Therapy;Annual Review of Pharmacology and Toxicology;2023-01-20